Shang‐Gin Wu

3.4k total citations · 1 hit paper
64 papers, 2.6k citations indexed

About

Shang‐Gin Wu is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Shang‐Gin Wu has authored 64 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Oncology, 45 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Shang‐Gin Wu's work include Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (24 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Shang‐Gin Wu is often cited by papers focused on Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (24 papers) and Lung Cancer Diagnosis and Treatment (13 papers). Shang‐Gin Wu collaborates with scholars based in Taiwan, China and United States. Shang‐Gin Wu's co-authors include Jin‐Yuan Shih, Chong‐Jen Yu, Pan‐Chyr Yang, James Chih‐Hsin Yang, Yih‐Leong Chang, Meng‐Feng Tsai, Chien‐Hung Gow, Jenn‐Yu Wu, Yinan Liu and Tzu‐Hua Chang and has published in prestigious journals such as PLoS ONE, American Journal of Respiratory and Critical Care Medicine and Scientific Reports.

In The Last Decade

Shang‐Gin Wu

62 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Management of acquired resistance to EGFR TKI–targeted therapy in advanced non-small cell lung cancer

2018 553 citations Shang‐Gin Wu, Jin‐Yuan Shih profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shang‐Gin Wu Taiwan	29	1.9k	1.5k	955	683	178	64	2.6k
Teresa Morán Spain	26	1.9k 1.0×	1.6k 1.1×	1.0k 1.1×	627 0.9×	145 0.8×	130	2.7k
Roberta Minari Italy	25	1.7k 0.9×	1.5k 1.0×	1.1k 1.2×	585 0.9×	134 0.8×	66	2.5k
Kenji Tomizawa Japan	26	1.5k 0.8×	1.3k 0.9×	874 0.9×	393 0.6×	288 1.6×	72	2.4k
Kazumi Nishino Japan	25	1.6k 0.8×	1.4k 0.9×	661 0.7×	735 1.1×	127 0.7×	164	2.3k
Felice Mucilli Italy	16	1.5k 0.8×	1.1k 0.7×	756 0.8×	464 0.7×	183 1.0×	59	2.0k
Alessandro Leonetti Italy	18	1.2k 0.6×	1.1k 0.8×	848 0.9×	424 0.6×	107 0.6×	54	2.0k
Francesco Facchinetti Italy	25	1.2k 0.6×	1.1k 0.8×	827 0.9×	386 0.6×	112 0.6×	79	2.1k
Hai‐Yan Tu China	23	2.4k 1.2×	2.2k 1.5×	695 0.7×	716 1.0×	157 0.9×	114	3.1k
Liza C. Villaruz United States	23	1.2k 0.6×	1.3k 0.9×	675 0.7×	422 0.6×	148 0.8×	81	2.0k
Michèle Beau‐Faller France	22	1.6k 0.8×	1.3k 0.9×	758 0.8×	554 0.8×	108 0.6×	61	2.1k

Countries citing papers authored by Shang‐Gin Wu

Since Specialization

Citations

This map shows the geographic impact of Shang‐Gin Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shang‐Gin Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shang‐Gin Wu more than expected).

Fields of papers citing papers by Shang‐Gin Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shang‐Gin Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shang‐Gin Wu. The network helps show where Shang‐Gin Wu may publish in the future.

Co-authorship network of co-authors of Shang‐Gin Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Shang‐Gin Wu. A scholar is included among the top collaborators of Shang‐Gin Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shang‐Gin Wu. Shang‐Gin Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Liao, Wei‐Yu, Chao‐Chi Ho, Shang‐Gin Wu, et al.. (2025). Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective study. European Journal of Cancer. 217. 115224–115224. 1 indexed citations

Hsu, Chia‐Chi, et al.. (2025). Identification of the molecular characterization and tumor microenvironment of thoracic inflammatory myofibroblastic tumors. Journal of the Formosan Medical Association. 125(4). 398–405.

Wu, Shang‐Gin, Chao‐Chi Ho, James Chih‐Hsin Yang, et al.. (2024). Atezolizumab, bevacizumab, pemetrexed and platinum for EGFR‐mutant NSCLC patients after EGFR TKI failure: A phase II study with immune cell profile analysis. Clinical and Translational Medicine. 15(1). e70149–e70149. 4 indexed citations

Chen, Yi‐Ling, Yinan Liu, Yen‐Ting Lin, et al.. (2023). LncRNA SLCO4A1-AS1 suppresses lung cancer progression by sequestering the TOX4-NTSR1 signaling axis. Journal of Biomedical Science. 30(1). 80–80. 14 indexed citations

Wu, Shang‐Gin, Tzu‐Hua Chang, Meng‐Feng Tsai, et al.. (2023). miR-204 suppresses cancer stemness and enhances osimertinib sensitivity in non-small cell lung cancer by targeting CD44. Molecular Therapy — Nucleic Acids. 35(1). 102091–102091. 12 indexed citations

Yang, Ching‐Yao, Jin‐Yuan Shih, Wei‐Yu Liao, et al.. (2023). Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system. European Journal of Cancer. 193. 113310–113310. 5 indexed citations

Wu, Shang‐Gin, et al.. (2023). Different treatment efficacies and T790M acquisition of EGFR‐TKIs on NSCLC patients with variable Del‐19 subtypes of EGFR. International Journal of Cancer. 153(2). 352–363. 4 indexed citations

Lin, Yen‐Ting, Chao‐Chi Ho, Wei‐Hsun Hsu, et al.. (2023). Tissue or liquid rebiopsy? A prospective study for simultaneous tissue and liquid NGS after first‐line EGFR inhibitor resistance in lung cancer. Cancer Medicine. 13(1). e6870–e6870. 4 indexed citations

Tsai, Tzu‐Hsiu, Chien‐Hung Gow, Meng‐Feng Tsai, et al.. (2023). MiR‐503 pleiotropically regulates epithelial‐mesenchymal transition and targets PTK7 to control lung cancer metastasis. Cancer Medicine. 12(13). 14511–14525. 6 indexed citations

10.

Liao, Bin-Chi, Wei‐Hsun Hsu, Ching‐Yao Yang, et al.. (2023). Effects of Early Short-Course Corticosteroids on Immune-Related Adverse Events in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Oncology. 102(4). 318–326. 5 indexed citations

11.

Lin, Ching‐Kai, et al.. (2021). Cone-Beam Computed Tomography-Derived Augmented Fluoroscopy Improves the Diagnostic Yield of Endobronchial Ultrasound-Guided Transbronchial Biopsy for Peripheral Pulmonary Lesions. Diagnostics. 12(1). 41–41. 12 indexed citations

12.

Wu, Shang‐Gin, Tzu‐Hua Chang, Yinan Liu, & Jin‐Yuan Shih. (2019). MicroRNA in Lung Cancer Metastasis. Cancers. 11(2). 265–265. 59 indexed citations

13.

Wu, Shang‐Gin, et al.. (2018). Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. Genes Chromosomes and Cancer. 57(10). 513–521. 14 indexed citations

14.

Gow, Chien‐Hung, Min‐Shu Hsieh, Shang‐Gin Wu, & Jin‐Yuan Shih. (2016). A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population. Lung Cancer. 103. 82–89. 51 indexed citations

15.

Lin, Yen‐Ting, Yu‐Fen Wang, James Chih‐Hsin Yang, et al.. (2014). Development of Renal Cysts after Crizotinib Treatment in Advanced ALK-Positive Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(11). 1720–1725. 44 indexed citations

16.

Chung, Kuei‐Pin, Shang‐Gin Wu, Jenn‐Yu Wu, et al.. (2012). Clinical Outcomes in Non–Small Cell Lung Cancers Harboring Different Exon 19 Deletions in EGFR. Clinical Cancer Research. 18(12). 3470–3477. 54 indexed citations

17.

Wu, Shang‐Gin, Chong‐Jen Yu, Meng‐Feng Tsai, et al.. (2012). Survival of lung adenocarcinoma patients with malignant pleural effusion. European Respiratory Journal. 41(6). 1409–1418. 79 indexed citations

18.

Wu, Shang‐Gin, Yao-Wen Kuo, Yih‐Leong Chang, et al.. (2011). EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR. Journal of Thoracic Oncology. 7(1). 98–104. 80 indexed citations

19.

Wu, Jenn‐Yu, Shang‐Gin Wu, James Chih‐Hsin Yang, et al.. (2010). Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations. Lung Cancer. 72(2). 205–212. 63 indexed citations

20.

Wu, Jenn‐Yu, Chong‐Jen Yu, James Chih‐Hsin Yang, et al.. (2008). First- or Second-line Therapy with Gefitinib Produces Equal Survival in Non–Small Cell Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 178(8). 847–853. 60 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact